Zacks: Analysts Expect Redhill Biopharma Ltd. (RDHL) to Post -$0.76 EPS
Wall Street brokerages expect that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report earnings of ($0.76) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Redhill Biopharma’s earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($0.80). Redhill Biopharma reported earnings of ($0.70) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The company is expected to report its next quarterly earnings results on Monday, November 13th.
According to Zacks, analysts expect that Redhill Biopharma will report full-year earnings of ($2.64) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.58). For the next financial year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($2.50) to ($2.05). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Redhill Biopharma.
Redhill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.34 million.
RDHL has been the topic of several research reports. Zacks Investment Research downgraded shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, July 29th. Roth Capital set a $27.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Monday, July 31st. FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, UBS AG initiated coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $23.69.
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC boosted its position in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. D.A. Davidson & CO. boosted its position in Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in Redhill Biopharma in the 1st quarter worth approximately $276,000. Family Management Corp boosted its position in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in Redhill Biopharma by 10.8% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 10.99% of the company’s stock.
Redhill Biopharma (NASDAQ:RDHL) traded up 7.56% during trading on Thursday, hitting $10.81. 345,796 shares of the company were exchanged. The firm’s 50 day moving average price is $8.65 and its 200-day moving average price is $9.37. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.74. The stock’s market capitalization is $185.74 million.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.